BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
4.090
-0.060 (-1.45%)
At close: Sep 22, 2026, 4:00 PM EDT
4.150
+0.060 (1.47%)
After-hours: Sep 22, 2026, 7:30 PM EDT
BriaCell Therapeutics Employees
BriaCell Therapeutics had 16 employees as of July 31, 2023. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change
10
Growth
166.67%
Revenue / Employee
n/a
Profits / Employee
-$1,917,204
Market Cap
35.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2023 | 16 | 10 | 166.67% | 16 | 0 |
| Jul 31, 2021 | 6 | 0 | - | 5 | 1 |
| Aug 1, 2019 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| Actinium Pharmaceuticals | 27 |
| Filana Therapeutics | 20 |
| Veru Inc. | 20 |
| CervoMed | 15 |
| Context Therapeutics | 15 |
BCTX News
- 8 days ago - BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook - GuruFocus
- 8 days ago - BriaCell announces DSMB recommendation to continue Bria-ABC study - TheFly
- 8 days ago - Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study - GlobeNewsWire
- 14 days ago - BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - GlobeNewsWire
- 4 weeks ago - BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics - GuruFocus
- 4 weeks ago - BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+ - TheFly
- 4 weeks ago - BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - GlobeNewsWire
- 6 weeks ago - BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer - TheFly